10-Q: Agenus Reports Q3 Profit Amid Strategic Asset Sales

Agenus Inc. reported a net income of $63.86 million for Q3 2025, driven by a significant gain from the deconsolidation of MiNK Therapeutics and reduced operating expenses, despite ongoing liquidity concerns.

Summary

• Agenus Inc. reported a net income attributable to common stockholders of $63.86 million for the three months ended September 30, 2025, a significant improvement from a net loss of $66.44 million in the prior year period.
• For the nine months ended September 30, 2025, net income attributable to common stockholders was $10.53 million, compared to a net loss of $181.51 million for the same period in 2024.
• The positive net income was primarily driven by a $100.9 million gain from the deconsolidation of MiNK Therapeutics, Inc. in July 2025, as Agenus's ownership dropped below 50%.
• Total revenues increased to $30.24 million for Q3 2025 from $25.11 million in Q3 2024, and to $79.99 million for the nine months ended September 30, 2025, from $76.63 million in the prior year period.
• Non-cash royalty revenue from GSK's vaccines containing STIMULON QS-21 adjuvant increased to $29.15 million in Q3 2025 from $24.66 million in Q3 2024, and to $77.54 million for the nine months ended September 30, 2025, from $75.01 million in the prior year period.
• Research and development (R&D) expenses decreased by 43% to $23.60 million in Q3 2025 and by 41% to $71.83 million for the nine months ended September 30, 2025, primarily due to reduced third-party services, lower personnel expenses, and the deconsolidation of MiNK.
• General and administrative (G&A) expenses decreased by 37% to $10.86 million in Q3 2025 and by 17% to $42.10 million for the nine months ended September 30, 2025, also due to decreased headcount and the deconsolidation of MiNK.
• Cash and cash equivalents stood at $3.46 million as of September 30, 2025, down from $40.44 million at December 31, 2024.
• Subsequent to quarter-end, Agenus secured a $10.0 million Promissory Note Agreement with Zydus Pharmaceuticals and received $4.5 million from at-the-market (ATM) common stock sales.
• The company anticipates receiving an additional $91.0 million from agreements with Zydus Lifesciences Ltd and its affiliates in the first quarter of 2026.
• Agenus entered into an Asset Purchase Agreement with Zydus for the sale of substantially all manufacturing operations assets for $75.0 million at closing, plus up to $50.0 million in contingent payments, expected to close in Q1 2026.
• The company continues to face 'substantial doubt' about its ability to continue as a going concern for one year from the filing date, despite anticipated funding, due to the completion of cash funding transactions not being entirely within its control.
• UroGen Pharma Ltd. notified Agenus in November 2025 of its termination of the license agreement for zalifrelimab.
• Incyte Corporation notified Agenus in February 2025 of its intent to terminate the entire Collaboration Agreement, effective February 2026, with rights to programs reverting to Agenus.
• Bristol-Myers Squibb Company (BMS) voluntarily terminated its License Agreement for AGEN1777, effective January 26, 2025, with rights reverting to Agenus.

Sentiment

Score: 5

Explanation: The filing presents a mixed picture. While the company achieved net income due to a one-time gain and showed significant cost reductions, its cash position remains low, and it continues to carry a 'going concern' warning. The strategic asset sale and new funding provide a lifeline, but the termination of multiple key collaboration agreements adds uncertainty to the pipeline's future and revenue streams. The legal proceedings also represent an unquantified risk.

Positives

• Achieved a net income of $63.86 million for Q3 2025, a significant turnaround from a $66.44 million loss in Q3 2024.
• Recognized a substantial $100.9 million gain from the deconsolidation of MiNK Therapeutics, Inc., contributing significantly to the positive financial results.
• Successfully reduced Research and Development expenses by 43% in Q3 2025 and 41% for the nine months ended September 30, 2025, indicating cost management.
• General and Administrative expenses also saw a notable decrease of 37% in Q3 2025 and 17% for the nine months ended September 30, 2025.
• Non-cash royalty revenue from GSK's STIMULON QS-21 adjuvant increased, reflecting strong sales of GSK's SHINGRIX and AREXVY vaccines.
• Secured $10.0 million through a Promissory Note Agreement with Zydus Pharmaceuticals and $4.5 million from at-the-market stock offerings post-quarter end, providing immediate liquidity.
• Anticipates a significant cash inflow of $91.0 million from Zydus agreements in Q1 2026, which includes $75.0 million from the sale of manufacturing assets and $16.0 million from a stock purchase.
• Botensilimab (BOT) in combination with balstilimab (BAL) received Fast Track designation from the FDA for metastatic colorectal cancer, highlighting regulatory progress for a lead asset.

Negatives

• Cash and cash equivalents decreased significantly to $3.46 million at September 30, 2025, from $40.44 million at December 31, 2024.
• Net cash used in operating activities for the nine months ended September 30, 2025, was $60.58 million, indicating continued cash burn from operations.
• Accumulated deficit remains substantial at $2.2 billion as of September 30, 2025.
• UroGen Pharma Ltd. terminated its license agreement for zalifrelimab in November 2025, leading to the loss of potential future revenues from this partnership.
• Incyte Corporation is terminating its entire Collaboration Agreement, effective February 2026, resulting in the reversion of program rights and loss of potential milestone payments.
• Bristol-Myers Squibb Company (BMS) voluntarily terminated its License Agreement for AGEN1777, effective January 26, 2025, causing the return of the program and loss of future milestones/royalties.
• The company continues to disclose 'substantial doubt' about its ability to continue as a going concern for a period of one year after the filing date, despite recent and anticipated funding.
• A $20.3 million MiNK investment fair value adjustment contributed to non-operating expense for the three and nine months ended September 30, 2025.

Risks

• Substantial doubt exists about the ability to continue as a going concern for a period of one year after the date of filing, as the completion of cash funding transactions is not entirely within the company's control.
• The company has incurred significant losses since inception, with an accumulated deficit of $2.2 billion as of September 30, 2025, and expects to incur significant losses for several more years.
• Reliance on additional funding sources, including out-licensing agreements, asset sales, project financing, and/or sales of equity securities, to support ongoing operations.
• Product candidates require successful clinical trials and approvals from regulatory agencies, as well as market acceptance, which are lengthy, expensive, and uncertain processes.
• The company is subject to a putative securities class action lawsuit alleging false and misleading statements related to the efficacy and commercial prospects of botensilimab and balstilimab, with an inability to estimate a range of loss.
• Four derivative actions have been filed by purported stockholders, making similar allegations against executives and directors, with an inability to estimate a range of loss.
• Received a subpoena from the SEC seeking records relating to product candidates, FDA correspondence, and public disclosure, with an inability to predict the outcome of the investigation.
• Termination of key collaboration agreements (UroGen, Incyte, BMS) means the company loses potential milestone payments and royalties, and must decide whether to continue developing these programs internally, which requires additional resources.
• Exposure to foreign currency exchange rate fluctuation risk, primarily concentrated in the British Pound, without specific hedging strategies in place.

Future Outlook

The company believes that its cash resources of $3.5 million at September 30, 2025, combined with post-quarter cash infusions ($10.0 million Zydus Note, $4.5 million from ATM sales), anticipated revenues from compassionate access in France, and projected additional cash inflows of $91.0 million from Zydus agreements in Q1 2026, will be sufficient to satisfy critical liquidity requirements through 2026. However, substantial doubt continues to exist about the ability to continue as a going concern for one year from the filing date, as the completion of cash funding transactions is not entirely within the company's control. Management is actively seeking additional funding through out-licensing agreements, asset sales, project financing, and/or equity sales to support operations through the planned registration and launch strategy for botensilimab/balstilimab.

Management Comments

• "Based on our current plans and projections, we believe that our cash resources of $3.5 million at September 30, 2025, along with the post-quarter cash infusions noted above, anticipated revenues under our reimbursed compassionate access in France, and projected additional cash inflows from funding we expect to receive in 2026, will be sufficient to satisfy our critical liquidity requirements through 2026."
• "Management continues to diligently address the Company's liquidity needs and has continued to adjust spending in order to preserve liquidity."
• "We expect our sources of funding to include additional out-licensing agreements, asset sales, project financing, and/or sales of equity securities."
• "Currently we are in discussions with entities including operating companies and financial entities to provide the additional funding to support our operations through our planned registration and launch strategy for botensilimab/balstilimab."

Industry Context

Agenus operates in the highly competitive and capital-intensive immuno-oncology and vaccine adjuvant sectors of the biotechnology industry. The strategic shift towards monetizing non-core assets (manufacturing facility) and reducing R&D/G&A expenses reflects a broader industry trend among clinical-stage biotechs to conserve capital and focus on lead assets, especially in a challenging funding environment. The termination of multiple collaboration agreements (Incyte, BMS, UroGen) highlights the inherent risks and high attrition rates in drug development partnerships, placing more burden on Agenus to advance these programs independently or find new partners. The continued success of GSK's vaccines utilizing Agenus's QS-21 adjuvant demonstrates the value of established platforms, providing a stable, albeit non-cash, revenue stream.

Comparison to Industry Standards

• NA The filing does not provide specific industry benchmarks or comparable company data to assess Agenus's financial results or clinical program progress against industry standards. Direct comparisons would require external market data and competitor analysis not present in this document.

Management Changes

Corporate Governance

Legal Proceedings

• A putative securities class action lawsuit (In re Agenus Inc. Securities Litigation, No. 1:24-cv-12299) was filed in September 2024, alleging false and misleading statements regarding botensilimab and balstilimab efficacy and commercial prospects. Agenus moved to dismiss on April 8, 2025, with the motion currently pending.
• Four derivative actions were filed between November 2024 and January 2025, consolidated in Case No. 1:24-cv-12823, making similar allegations against executives and directors. These actions are stayed pending developments in the securities class action.
• Received a subpoena from the Boston Regional Office of the U.S. Securities and Exchange Commission (SEC) in September 2024, seeking records related to product candidates, FDA correspondence, and public disclosure. Records have been produced, but the outcome of the investigation is unpredictable.

Related Party Transactions

• Maintains an equity method investment in MiNK Therapeutics, Inc. (approximately 48% ownership as of September 30, 2025) and provides intercompany services under an Amended and Restated Intercompany Services Agreement.
• Holds a related party note receivable from MiNK Therapeutics, Inc. with a principal balance of $5.0 million and accrued interest of approximately $154,000 as of September 30, 2025.
• Dr. Jennifer Buell, CEO of MiNK, was appointed to Agenus's Board of Directors in June 2024. Her spouse is a partner at Wolf, Greenfield & Sachs, P.C., which provides legal services to Agenus. Fees paid to Wolf Greenfield were approximately $4,000 for Q3 2025 and $167,000 for YTD Sept 2025, approved by the Audit and Finance Committee.

Stakeholder Impact

• Shareholders: Experienced significant dilution from at-the-market offerings and face potential further dilution from future capital raises. The 'going concern' warning and legal proceedings introduce significant risk. However, the one-time gain and cost reductions offer some positive financial performance.
• Employees: Reduced personnel-related expenses indicate potential headcount reductions. Share-based compensation remains a component of employee incentives.
• Customers/Partners: Termination of multiple collaboration agreements (UroGen, Incyte, BMS) impacts the development and commercialization pathways for several product candidates, potentially affecting future availability or partnerships.
• Creditors: The company has substantial debt maturing in 2026 ($10.5 million in June 2026, $24.75 million in November 2026), and the 'going concern' warning indicates elevated credit risk, though recent and anticipated funding may alleviate immediate concerns.

Next Steps

• Complete strategic transactions to secure additional funding for botensilimab/balstilimab registration and launch.
• Launch registration-enabling trials for botensilimab/balstilimab in Microsatellite Stable colorectal cancer.
• Close the Asset Purchase Agreement and Securities Purchase Agreement with Zydus Lifesciences Ltd and its affiliates in Q1 2026.
• Continue to diligently address liquidity needs and adjust spending to preserve cash.
• Evaluate development, commercialization, and partnering strategies for product candidates whose rights have reverted from terminated collaborations (Incyte, BMS, UroGen).
• Monitor and respond to ongoing legal proceedings, including the securities class action, derivative actions, and SEC subpoena.

Key Dates

Recommendation

Agenus's Q3 2025 results show a significant net income, primarily due to a one-time gain from the deconsolidation of MiNK Therapeutics and substantial reductions in operating expenses. This, coupled with recent and anticipated capital infusions from Zydus, provides a near-term liquidity runway through 2026, which is a positive development given the persistent 'going concern' warning. However, the termination of multiple key collaboration agreements (Incyte, BMS, UroGen) introduces considerable uncertainty regarding the future development and commercialization of several pipeline assets, requiring the company to either re-partner or fund these programs internally. The ongoing legal proceedings and SEC investigation also represent unquantified risks. While cost controls and the Zydus deal are favorable, the long-term financial stability and pipeline execution remain challenging. Therefore, a 'hold' recommendation is appropriate, acknowledging the positive short-term financial maneuvers while recognizing the significant strategic and operational hurdles ahead.

Keywords

Agenus, Biotechnology, Immuno-oncology, Botensilimab, Balstilimab, CTLA-4, PD-1, STIMULON QS-21, MiNK Therapeutics, SEC 10-Q, Financial Results, Clinical Stage, Asset Sale, Liquidity, Going Concern, Zydus, FDA Fast Track, Cancer Therapy, Vaccine Adjuvant